Key Details
Price
$5.38Annual ROE
36.83%Beta
2.22Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
N/ARecent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=125334&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESS Newswire / January 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO") conducted on September 26, 2024, are encouraged to contact the firm before March 10, 2025.
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=125284&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and prospects of a key drug candidate before its initial public offering last September. Hagens Berman urges investors who purchased BioAge shares in the company's IPO or on the open market and suffered substantial losses to submit your losses now.
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=125258&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , Jan. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA). Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=125226&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=125197&wire=1 or contact Joseph E. Levi, Esq.
RADNOR, Pa., Jan. 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against BioAge Labs, Inc. (“BioAge”) (NASDAQ: BIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). The lead plaintiff deadline is March 10, 2025.
FAQ
- What is the primary business of BioAge Labs?
- What is the ticker symbol for BioAge Labs?
- Does BioAge Labs pay dividends?
- What sector is BioAge Labs in?
- What industry is BioAge Labs in?
- What country is BioAge Labs based in?
- When did BioAge Labs go public?
- Is BioAge Labs in the S&P 500?
- Is BioAge Labs in the NASDAQ 100?
- Is BioAge Labs in the Dow Jones?
- When does BioAge Labs report earnings?